{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:00:48Z","timestamp":1781064048125,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Parasit."],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11686-026-01227-y","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:14:21Z","timestamp":1771434861000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful Management of Refractory toxoplasmosis-related Macular Neovascularization with Intravitreal Faricimab"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4651-8177","authenticated-orcid":false,"given":"\u015eefik Can","family":"\u0130pek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8235-4088","authenticated-orcid":false,"given":"Seher","family":"K\u00f6ksald\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2059-0696","authenticated-orcid":false,"given":"Mustafa","family":"Kayaba\u015f\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5108-0069","authenticated-orcid":false,"given":"Cem","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"1227_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000512286","volume":"12","author":"NS Khandwala","year":"2021","unstructured":"Khandwala NS, Hyde RA, Besirli CG (2021) Toxoplasma retinochoroiditis with chorioretinal neovascularization in a young patient. Case Rep Ophthalmol 12:259\u2013263","journal-title":"Case Rep Ophthalmol"},{"key":"1227_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3109\/08820538.2013.838278","volume":"30","author":"F Kianersi","year":"2015","unstructured":"Kianersi F, Naderi Beni A, Naderi Beni Z, Ghanbari H (2015) Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to toxoplasmic retinochoroiditis: a case series. Semin Ophthalmol 30:181\u2013187","journal-title":"Semin Ophthalmol"},{"key":"1227_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s10384-003-0069-0","volume":"48","author":"LS Atmaca","year":"2004","unstructured":"Atmaca LS, Simsek T, Batioglu F (2004) Clinical features and prognosis in ocular toxoplasmosis. Jpn J Ophthalmol 48:386\u2013391","journal-title":"Jpn J Ophthalmol"},{"key":"1227_CR4","unstructured":"Rudzinski MN, Schlaen A, Chenlo M, Couto CA, Colombero D (2004) Retinal neovascularization in ocular toxoplasmosis."},{"key":"1227_CR5","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/archopht.126.8.1152","volume":"126","author":"JD Benevento","year":"2008","unstructured":"Benevento JD, Jager RD, Noble AG, Latkany P, Mieler WF, Sautter M et al (2008) Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol 126:1152\u20131156","journal-title":"Arch Ophthalmol"},{"key":"1227_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/j.1462-5822.2005.00628.x","volume":"8","author":"W Spear","year":"2006","unstructured":"Spear W, Chan D, Coppens I, Johnson RS, Giaccia A, Blader IJ (2006) The host cell transcription factor hypoxia-inducible factor 1 is required for Toxoplasma gondii growth and survival at physiological oxygen levels. Cell Microbiol 8:339\u2013352","journal-title":"Cell Microbiol"},{"key":"1227_CR7","volume":"17","author":"P Rao","year":"2005","unstructured":"Rao P, Rao A, Jaffer JM, John AS (2005) Intravitreal faricimab for the management of bilateral macular neovascularization secondary to macular telangiectasia type 2. Cureus 17:e92696","journal-title":"Cureus"},{"key":"1227_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10792-008-9291-6","volume":"30","author":"P Neri","year":"2010","unstructured":"Neri P, Mercanti L, Mariotti C, Salvolini S, Giovannini A (2010) Long-term control of choroidal neovascularization in quiescent congenital toxoplasma retinochoroiditis with photodynamic therapy: 4-year results. Int Ophthalmol 30:51\u201356","journal-title":"Int Ophthalmol"},{"key":"1227_CR9","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2147\/OPTH.S132923","volume":"11","author":"AR Korol","year":"2017","unstructured":"Korol AR, Zborovska O, Kustryn T, Dorokhova O, Pasyechnikova N (2017) Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study. Clin Ophthalmol 11:1315\u20131320","journal-title":"Clin Ophthalmol"},{"key":"1227_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4103\/0301-4738.82005","volume":"59","author":"NJ Shah","year":"2011","unstructured":"Shah NJ, Shah UN (2011) Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis. Indian J Ophthalmol 59:318\u2013319","journal-title":"Indian J Ophthalmol"},{"key":"1227_CR11","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1097\/IAE.0000000000001710","volume":"38","author":"P D\u02bcsouza","year":"2018","unstructured":"D\u02bcsouza P, Ranjan R, Babu U, Kanakath AV, Saravanan VR (2018) Inflammatory choroidal neovascular membrane: long-term visual and anatomical outcomes after intravitreal anti-vascular endothelial growth factor therapy. Retina 38:1307\u20131315","journal-title":"Retina"},{"key":"1227_CR12","volume":"2021","author":"G Carrola","year":"2021","unstructured":"Carrola G, Lima-Fontes M, Falc\u00e3o-Reis F, Figueira L, Carneiro \u00c2 (2021) Inflammatory choroidal neovascular membranes: clinical profile, treatment effectiveness, and visual prognosis. J Ophthalmol 2021:9982883","journal-title":"J Ophthalmol"},{"key":"1227_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4103\/0974-9233.58422","volume":"16","author":"P Neri","year":"2009","unstructured":"Neri P, Lettieri M, Fortuna C, Manoni M, Giovannini A (2009) Inflammatory choroidal neovascularization. Middle East Afr J Ophthalmol 16:245\u2013251","journal-title":"Middle East Afr J Ophthalmol"},{"key":"1227_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-015-0051-2","volume":"5","author":"S Hegde","year":"2015","unstructured":"Hegde S, Relhan N, Pathengay A, Bawdekar A, Choudhury H, Jindal A et al (2015) Coexisting choroidal neovascularization and active retinochoroiditis-an uncommon presentation of ocular toxoplasmosis. J Ophthalmic Inflamm Infect 5:22","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"1227_CR15","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1755-3768.2008.01319.x","volume":"87","author":"R Guthoff","year":"2009","unstructured":"Guthoff R, Goebel W (2009) Intravitreal bevacizumab for choroidal neovascularization in toxoplasmosis. Acta Ophthalmol 87:688\u2013690","journal-title":"Acta Ophthalmol"},{"key":"1227_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10792-008-9218-2","volume":"28","author":"S Ben Yahia","year":"2008","unstructured":"Ben Yahia S, Herbort CP, Jenzeri S, Hmidi K, Attia S, Messaoud R et al (2008) Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis. Int Ophthalmol 28:311\u2013316","journal-title":"Int Ophthalmol"},{"key":"1227_CR17","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/ICB.0b013e3181ff09ae","volume":"5","author":"CJ Lin","year":"2011","unstructured":"Lin CJ, Chen SN, Hwang JF, Hu PS (2011) Successful treatment of toxoplasmosis-associated choroidal neovascular lesions with bevacizumab and antiparasitic therapy. Retin Cases Brief Rep 5:348\u2013351","journal-title":"Retin Cases Brief Rep"},{"key":"1227_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/IAE.0b013e3181ed8cec","volume":"31","author":"JF Arevalo","year":"2011","unstructured":"Arevalo JF, Adan A, Berrocal MH, Espinoza JV, Maia M, Wu L et al (2011) Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months. Retina 31:353\u2013363","journal-title":"Retina"},{"key":"1227_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4103\/0974-620X.142598","volume":"7","author":"G Mathur","year":"2014","unstructured":"Mathur G, George AE, Sen P (2014) Paediatric choroidal neovascular membrane secondary to toxoplasmosis treated successfully with anti-vascular endothelial growth factor. Oman J Ophthalmol 7:141\u2013143","journal-title":"Oman J Ophthalmol"},{"key":"1227_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3129\/i10-123","volume":"46","author":"RP Kohly","year":"2011","unstructured":"Kohly RP, Muni RH, Kertes PJ, Lam WC (2011) Management of pediatric choroidal neovascular membranes with intravitreal anti-VEGF agents: a retrospective consecutive case series. Can J Ophthalmol 46:46\u201350","journal-title":"Can J Ophthalmol"},{"key":"1227_CR21","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1097\/IAE.0b013e3181c96a00","volume":"30","author":"M Kramer","year":"2010","unstructured":"Kramer M, Axer-Siegel R, Jaouni T, Reich E, Hemo I, Priel E et al (2010) Bevacizumab for choroidal neovascularization related to inflammatory diseases. Retina 30:938\u2013944","journal-title":"Retina"},{"key":"1227_CR22","volume":"11","author":"F Mushtaq","year":"2019","unstructured":"Mushtaq F, Ahmad A, Qambar F, Ahmad A, Zehra N (2019) Primary acquired toxoplasma retinochoroiditis: choroidal neovascular membrane as an early complication. Cureus 11:e4001","journal-title":"Cureus"},{"key":"1227_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/0301-4738.73728","volume":"59","author":"P Rishi","year":"2011","unstructured":"Rishi P, Venkataraman A, Rishi E (2011) Combination photodynamic therapy and bevacizumab for choroidal neovascularization associated with toxoplasmosis. Indian J Ophthalmol 59:62\u201364","journal-title":"Indian J Ophthalmol"},{"key":"1227_CR24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S2173-5794(10)70068-2","volume":"85","author":"M Cordero-Coma","year":"2010","unstructured":"Cordero-Coma M, P\u00e9rez E, Calleja S, de Morales JGR (2010) Toxoplasmic retinochoroiditis: relapse vs choroidal neovascular membrane. Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition) 85:410\u2013413","journal-title":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"},{"key":"1227_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.5301\/ejo.5000192","volume":"23","author":"L Iannetti","year":"2013","unstructured":"Iannetti L, Paroli MP, Fabiani C, Nardella C, Campanella M, Pivetti-Pezzi P (2013) Effects of intravitreal bevacizumab on inflammatory choroidal neovascular membrane. Eur J Ophthalmol 23:114\u2013118","journal-title":"Eur J Ophthalmol"},{"key":"1227_CR26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1097\/IAE.0b013e3182003ca8","volume":"31","author":"A Rouvas","year":"2011","unstructured":"Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I et al (2011) Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina 31:871\u2013879","journal-title":"Retina"},{"key":"1227_CR27","first-page":"391","volume":"9","author":"P Petrou","year":"2013","unstructured":"Petrou P, Georgalas I, Markomichelakis N, Vergados I, Gianakaki E, Rouvas A (2013) Resolution of vitreomacular traction following intravitreal ranibizumab in cases of ocular toxoplasmosis with choroidal neovascularization. Ther Clin Risk Manag 9:391\u2013394","journal-title":"Ther Clin Risk Manag"},{"key":"1227_CR28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.oftale.2019.11.002","volume":"95","author":"E Mart\u00edn Garc\u00eda","year":"2020","unstructured":"Mart\u00edn Garc\u00eda E, Ch\u00e1varri Garc\u00eda JJ, Rodr\u00edguez Vicente L, Jim\u00e9nez Del R\u00edo B, Guallar Leza SM, Del R\u00edo Mayor JL (2020) Management of the neovascular choroidal membrane secondary to ocular toxoplasmosis. Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition) 95:90\u201393","journal-title":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"},{"key":"1227_CR29","first-page":"1","volume":"81","author":"K Pavl\u00edkov\u00e1","year":"2025","unstructured":"Pavl\u00edkov\u00e1 K, Krej\u010d\u00ed\u0159ov\u00e1 I, Autrata R, \u0160enkov\u00e1 K, Matu\u0161kov\u00e1 V (2025) Choroidal neovascular membrane in pediatric patients: long-term outcomes of Anti-VEGF therapy. Cesk Slov Oftalmol 81:1\u20138","journal-title":"Cesk Slov Oftalmol"},{"key":"1227_CR30","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.2147\/OPTH.S34294","volume":"6","author":"AM Mansour","year":"2012","unstructured":"Mansour AM, Mackensen F, Mahendradas P, Khairallah M, Lai TY, Bashshur Z (2012) Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization. Clin Ophthalmol 6:1233\u20131237","journal-title":"Clin Ophthalmol"},{"key":"1227_CR31","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1177\/11206721211048799","volume":"32","author":"R Ranjan","year":"2022","unstructured":"Ranjan R, Salian R, Verghese S, Manayath GJ, D\u2019Souza P, Kanakath AV et al (2022) Pediatric choroidal neovascularization: etiology and treatment outcomes with anti-vascular endothelial growth factors. Eur J Ophthalmol 32:2355\u20132367","journal-title":"Eur J Ophthalmol"},{"key":"1227_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/09273948.2019.1576909","volume":"28","author":"SK Ganesh","year":"2020","unstructured":"Ganesh SK, Ahmed AS (2020) Pediatric inflammatory CNV: a case series from a tertiary referral centre. Ocul Immunol Inflamm 28:26\u201332","journal-title":"Ocul Immunol Inflamm"},{"key":"1227_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-025-00691-4","volume":"11","author":"A Heinke","year":"2025","unstructured":"Heinke A, Warter A, Nagel ID, Agnihotri A, Mehta NN, Galang CMB et al (2025) Faricimab for treatment-resistant choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD): seven-months results using artificial intelligence and OCTA. Int J Retina Vitreous 11:68","journal-title":"Int J Retina Vitreous"}],"container-title":["Acta Parasitologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11686-026-01227-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11686-026-01227-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11686-026-01227-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:21:33Z","timestamp":1781061693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11686-026-01227-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1227"],"URL":"https:\/\/doi.org\/10.1007\/s11686-026-01227-y","relation":{},"ISSN":["1230-2821","1896-1851"],"issn-type":[{"value":"1230-2821","type":"print"},{"value":"1896-1851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Written informed consent was obtained from the patient to include the ocular imaging, genetic testing results, and clinical data in the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"45"}}